

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450  
Alexandria, VA 22313 on December 22, 2006.

INFORMATION DISCLOSURE  
STATEMENT  
Patent Application  
Docket No. ARS-126  
Serial No. 10/573,369

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Philippe Dupraz, Michel Kobr  
Serial No. : 10/573,369  
Filed : March 24, 2006  
Conf. No. : 2134  
For : Leader Sequences for Use in Production of Proteins

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 AND 1.98


Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.  
Patent Attorney  
Registration No. 45,332  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of references cited therein.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/573,369
Sheet	1	of	3	Filing Date	March 26, 2006
				First Named Inventor	Philippe Dupraz
				Art Unit	
				Examiner Name	
				Attorney Docket Number	ARS-126

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
	F1	WO 99/53059 A1	10-21-1999	Genentech, Inc..	All
	F2	WO 00/47741 A1	08-17-2000	Amgen, Inc.	All
	F3	WO 00/52158 A1	08-09-2000	Cell Genesys, Inc.	All
	F4	EP 0 382 762 B1	12-15-1993	Edwards et al.	All
	F5				
	F6				
	F7				

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				<b>Complete if Known</b>	
Sheet	2	of	3	Application Number	10/573,369
				Filing Date	March 26, 2006
				First Named Inventor	Philippe Dupraz
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	ARS-126

<b>NON PATENT LITERATURE DOCUMENTS</b>		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	R1	Database EMBL 'Online!, Database Accession No. BD599618, ASHKENAZI, A.J., et al. "Secretion of glycosylated protein with the use of tissue plasminogen activator prosequence" July 17, 2003, XP002267400.
	R2	Database GENSEQ 'Online!, Database Accession No. AAY95831, MARTIN, F.H. et al. "Native mouse IgG1 signal peptide" November 7, 2000, XP002267401.
	R3	Database GENSEQ 'Online!, Database Accession No. AAY96081, PATEL, S. et al. "Mouse IgH signal peptide", December 5, 2000, XP002266931.
	R4	ETCHEVERRY, T. et al. "Thirteen Amino Acid Propeptide from Tissue Plasminogen Activator Improves Expression of Recombinant TNFr-IgG1", April 25-29, 1999, ESACT meeting, abstract, 01.07/P1.02.
	R5	KÖHNE, C. et al. "Secretion of Glycosylation Site Mutants Can be Rescued by the Signal/Pro Sequence of Tissue Plasminogen Activator", <i>Journal of Cellular Biochemistry</i> , 1999, pp. 446-461, Vol. 75.
	R6	NAKAYAMA, K. "Furin: A Mammalian Subtilisin/Kex2p-Like Endoprotease Involved in Processing of a Wide Variety of Precursor Proteins", <i>Biochem. J.</i> , 1997, pp. 625-635, Vol. 327.
	R7	PFEFFER, S. R. et al. "Biosynthetic Protein Transport and Sorting by the Endoplasmic Reticulum and Golgi", <i>Ann. Rev. Biochem.</i> , 1987, pp. 829-852, Vol. 56.
	R8	SEIDAH, N. G. et al. "Proprotein and Prohormone Convertases: a Family of Subtilases Generating Diverse Bioactive Polypeptides", <i>Brain Research</i> , 1999, pp. 45-62, Vol. 848.
	R9	SHOTWELL, M. A. et al. "Regulation of Amino Acid Transport System L in Chinese Hamster Ovary Cells", <i>The Journal of Biological Chemistry</i> , March 25, 1982, pp. 2974-2980, Vol. 257, No. 6.
	R10	THOMAS, G. "Furin at the Cutting Edge: From Protein Traffic to Embryogenesis and Disease", <i>Nature Reviews Molecular Cell Biology</i> , October 2002, pp. 753-766, Vol. 3.
	R11	WATANABE, T. et al. "Sequence Requirements for Precursor Cleavage within the Constitutive Secretory Pathway", <i>The Journal of Biological Chemistry</i> , April 25, 1992, pp. 8270-8274, Vol. 267, No. 12.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	3	of	3	Application Number	10/573,369
				Filing Date	March 26, 2006
				First Named Inventor	Philippe Dupraz
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	ARS-126

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	R12	LOH, D. Y. et al. "Molecular Basis of a Mouse Strain-Specific Anti-Hapten Response", <i>Cell</i> , May 1983, pp. 85-93, Vol. 33.		
	R13	SwissProt Accession No. P00750, "Tissue-Type Plasminogen Activator", July 1986, pp. 1-10.		
	R14	EMBL Accession No. M13331, WEAVER, D. et al. "Altered repertoire of endogenous immunoglobulin gene expression in transgenic mice containing a rearranged mu heavy chain gene", April 27, 1993.		
	R15			
	R16			
	R17			
	R18			
	R19			
	R20			
	R21			
	R22			
	R23			

Examiner Signature	Date Considered
--------------------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2